Mankind Pharma Limited announced that its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), has received approval from its members for voluntary liquidation. This decision, made during an Extraordinary General Meeting on September 7, 2026, is subject to creditor approval under the Insolvency and Bankruptcy Code. This marks a significant step in the planned restructuring process for BSVL.
BSVL Voluntary Liquidation Gains Member Approval
Mankind Pharma Limited has provided an update regarding the voluntary liquidation process of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL). Following preparatory activities previously communicated, the members of BSVL have officially approved the commencement of voluntary liquidation.
Key Decisions and Next Steps
The approval was formally granted during the Extraordinary General Meeting (EGM) of BSVL held on September 7, 2026. This resolution is contingent upon obtaining the necessary approval from the creditors of BSVL, in accordance with the provisions outlined in the Insolvency and Bankruptcy Code, 2016, and the Insolvency and Bankruptcy Board of India (Voluntary Liquidation Process) Regulations, 2017. This development represents a significant milestone in the company’s strategic restructuring initiatives.
Source: BSE
